UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Role of phloretin as a sensitizer to TRAIL‑induced apoptosis in colon cancer

Oncology letters, 2022-09, Vol.24 (3), p.1, Article 321

2022

Volltextzugriff (PDF)

BMP-2 induces motility and invasiveness by promoting colon cancer stemness through STAT3 activation

Tumor biology, 2015-12, Vol.36 (12), p.9475-9486

2015

Volltextzugriff (PDF)

A phase III study of nivolumab (Nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Three-year update data

Journal of clinical oncology, 2020-02, Vol.38 (4_suppl), p.383-383

2020

Volltextzugriff (PDF)

Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastro-esophageal junction cancer (AGC): A double-blinded, randomized, phase III trial

Journal of clinical oncology, 2017-02, Vol.35 (4_suppl), p.2-2

2017

Volltextzugriff (PDF)

409 Trial in progress: a phase 2 study to assess the safety, efficacy of FLX475 combined with pembrolizumab in patients with advanced or metastatic gastric cancer

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A440-A440

2021

Volltextzugriff (PDF)

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet (British edition), 2023-06, Vol.401 (10391), p.1853-1865

2023

Volltextzugriff (PDF)

Development of hand-food skin reaction correlates with prognosis of patients with HCC who were treated with sorafenib

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e16171-e16171

2022

Volltextzugriff (PDF)

Korean red ginseng for cancer-related fatigue in colorectal cancer patients with chemotherapy: A randomised phase III trial

European journal of cancer (1990), 2020-05, Vol.130, p.51-62

2020

Volltextzugriff (PDF)

Cannabidiol Enhances Atezolizumab Efficacy by Upregulating PD-L1 Expression via the cGAS–STING Pathway in Triple-Negative Breast Cancer Cells

Cancer immunology research, 2024-09, p.OF1-OF12

2024

Volltextzugriff (PDF)

Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) and tislelizumab (TIS) as first-line (1L) therapy for patients (pts) with advanced HER2-positive gastric/gastroesophageal junction adenocarcinoma (G/GEJC): Preliminary results from a phase 1b/2 study

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.4032-4032

2022

Volltextzugriff (PDF)

Randomized phase II study of nalicap (nal-IRI/capecitabine) compared to NAPOLI (nal-IRI/5-FU/LV) in gemcitabine-pretreated advanced pancreatic cancer: Trial-in-progress

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.TPS621-TPS621

2022

Volltextzugriff (PDF)

Abstract 899: Phosphorylated mTOR by signaling through EphB3 confers resistance to a selective FGFR inhibitor in SNU-16 gastric cancer cells

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.899-899

2018

Volltextzugriff (PDF)

Health-related quality of life (HRQoL) in the phase 3 KEYNOTE-966 study of pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) versus placebo plus gem/cis for advanced biliary tract cancer (BTC)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.4003-4003

2023

Volltextzugriff (PDF)

Outcomes by antibiotic use in participants with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase 3 TOPAZ-1 study

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.550-550

2023

Volltextzugriff (PDF)

Neoadjuvant docetaxel, oxaliplatin, and s-1 plus surgery and adjuvant s-1 for resectable advanced gastric cancer: Final survival outcomes of the randomized phase 3 PRODIGY trial

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.4067-4067

2023

Volltextzugriff (PDF)

MO36-4 Asian subgroup analysis in global POLAR program of calmangafodipir on top of mFOLFOX6 for the prevention of CIPN

Annals of oncology, 2022-07, Vol.33, p.S504

2022

Volltextzugriff (PDF)

Abstract B032: The study of the role of Romo1 for angiogenesis/lymphangiogenesis in colorectal cancer

Molecular cancer therapeutics, 2018-01, Vol.17 (1_Supplement), p.B032-B032

2018

Volltextzugriff (PDF)

Abstract 2254: Reactive oxygen species modulator 1 (Romo1) predicts unfavorable prognosis in colorectal cancer patients

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.2254-2254

2017

Volltextzugriff (PDF)

Abstract 5327: Glioma derived cancer stem cells are hypersensitive to proteasomal inhibition

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.5327-5327

2017

Volltextzugriff (PDF)

Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT)

Journal of clinical oncology, 2021-01, Vol.39 (3_suppl), p.160-160

2021

Volltextzugriff (PDF)

Interim analysis of fluorodeoxyglucose uptake in patients with metastatic or recurrent gastric cancer treated with fluoropyrimidine based chemotherapy

Journal of clinical oncology, 2015-01, Vol.33 (3_suppl), p.44-44

2015

Volltextzugriff (PDF)

Novel Systemic Therapies for Advanced Gastric Cancer

Journal of gastric cancer, 2018, Vol.18 (1), p.1-19

2018

Volltextzugriff (PDF)

Open-label, phase II study of ladiratuzumab vedotin (LV) for castration-resistant prostate cancer (SGNLVA-005, trial-in-progress)

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.TPS185-TPS185

2021

Volltextzugriff (PDF)

Zanidatamab, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: A phase 1B/2 trial-in-progress

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS2656-TPS2656

2021

Volltextzugriff (PDF)

1 – 25 von 146

Suche als RSS-Feed

Aktive Filter

ThemaAged

ThemaScience & Technology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(129)
Mit Volltextzugriff
(126)

Publikationsform

Artikel
(145)
Berichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(8)
Cancer
(5)
Chemotherapy
(5)
의약학
(5)
Animals
(4)
Apoptosis
(4)
Apoptosis - Drug Effects
(4)
Colonic Neoplasms - Pathology
(4)
Colorectal Cancer
(4)
Metastasis
(4)
Nf-Kappa B - Metabolism
(4)
Cell Line, Tumor
(3)
Cell Proliferation - Drug Effects
(3)
Colonic Neoplasms - Metabolism
(3)
Hct116 Cells
(3)
Male
(3)
Metastases
(3)
Mice
(3)
Nf-Kappa B - Antagonists & Inhibitors
(3)
Prognosis
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Role of phloretin as a sensitizer to TRAIL‑induced apoptosis in colon cancer

BMP-2 induces motility and invasiveness by promoting colon cancer stemness through STAT3 activation

A phase III study of nivolumab (Nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Three-year update data

Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastro-esophageal junction cancer (AGC): A double-blinded, randomized, phase III trial

409 Trial in progress: a phase 2 study to assess the safety, efficacy of FLX475 combined with pembrolizumab in patients with advanced or metastatic gastric cancer

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

Development of hand-food skin reaction correlates with prognosis of patients with HCC who were treated with sorafenib

Korean red ginseng for cancer-related fatigue in colorectal cancer patients with chemotherapy: A randomised phase III trial

Cannabidiol Enhances Atezolizumab Efficacy by Upregulating PD-L1 Expression via the cGAS–STING Pathway in Triple-Negative Breast Cancer Cells

Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) and tislelizumab (TIS) as first-line (1L) therapy for patients (pts) with advanced HER2-positive gastric/gastroesophageal junction adenocarcinoma (G/GEJC): Preliminary results from a phase 1b/2 study

Randomized phase II study of nalicap (nal-IRI/capecitabine) compared to NAPOLI (nal-IRI/5-FU/LV) in gemcitabine-pretreated advanced pancreatic cancer: Trial-in-progress

Abstract 899: Phosphorylated mTOR by signaling through EphB3 confers resistance to a selective FGFR inhibitor in SNU-16 gastric cancer cells

Health-related quality of life (HRQoL) in the phase 3 KEYNOTE-966 study of pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) versus placebo plus gem/cis for advanced biliary tract cancer (BTC)

Outcomes by antibiotic use in participants with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase 3 TOPAZ-1 study

Neoadjuvant docetaxel, oxaliplatin, and s-1 plus surgery and adjuvant s-1 for resectable advanced gastric cancer: Final survival outcomes of the randomized phase 3 PRODIGY trial

MO36-4 Asian subgroup analysis in global POLAR program of calmangafodipir on top of mFOLFOX6 for the prevention of CIPN

Abstract B032: The study of the role of Romo1 for angiogenesis/lymphangiogenesis in colorectal cancer

Abstract 2254: Reactive oxygen species modulator 1 (Romo1) predicts unfavorable prognosis in colorectal cancer patients

Abstract 5327: Glioma derived cancer stem cells are hypersensitive to proteasomal inhibition

Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT)

Interim analysis of fluorodeoxyglucose uptake in patients with metastatic or recurrent gastric cancer treated with fluoropyrimidine based chemotherapy

Novel Systemic Therapies for Advanced Gastric Cancer

Open-label, phase II study of ladiratuzumab vedotin (LV) for castration-resistant prostate cancer (SGNLVA-005, trial-in-progress)

Zanidatamab, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: A phase 1B/2 trial-in-progress

Aktive Filter

Suchergebnisse filtern